# Refine Search

### Search Results -

Terms	Documents
(hspc same cholesterol same dspg) and cisplatin	12

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database

Database:


US OCR Full-Text Database EPO Abstracts Database JPO Abstracts Database Derwent World Patents Index

IBM Technical Disclosure Bulletins

Search:

5	
	K









## **Search History**

DATE: Thursday, March 08, 2007 Purge Queries Printable Copy Create Case

Set Name side by side		Hit Count	Set Name result set
DB=PG	PB, USPT, USOC, EPAB, JPAB, DWPI, TDBD; PLUR=YE	ES; $OP = OR$	
<u>L5</u>	(hspc same cholesterol same dspg) and cisplatin	12	<u>L5</u>
<u>L4</u>	hspc same cholesterol same cisplatin same dspg	0	<u>L4</u>
<u>L3</u>	dmpc same cholesterol same cisplatin same dspg	0	<u>L3</u>
<u>L2</u>	dopc same cholesterol same cisplatin	1	<u>L2</u>
1.1	liposome same donc same cholesterol same cisplatin	0	T.1

**END OF SEARCH HISTORY** 

First Hit Previous Doc Next Doc Go to Doc#

Generate Collection Pulse

Pulse

First Hit Previous Doc Go to Doc#

L5: Entry 10 of 12 File: PGPB Mar 21, 2002

DOCUMENT-IDENTIFIER: US 20020034538 A1

TITLE: Liposomal benzoquinazolne thymidylate synthase inhibitor formulations

## Detail Description Paragraph:

[0086] Inhibition of the growth of tumors associated with all cancers is contemplated by this invention, including multiple drug resistant cancer. Cancers for which the described liposomal formulations may be particularly useful in inhibiting are colorectal, ovarian, lung, breast, head and neck, prostate, uteran, glioblastoma, and sarcomas. In addition, it is contemplated that the formulations described and claimed herein can be used in combination with other anticancer treatments, including, but not limited to, 1) taxol (paclitaxel) and platinum complexes for treating ovarian cancer; 2) 5FU and leucovorin or levamisole for treating colorectal cancer; 3) cisplatin and etoposide for treating lung, 4) topo I inhibitors such as topotecan, irinotecan, and NX211, and 5) anthracyclines, such as doxorubicin or doxil.

#### Detail Description Table CWU:

3TABLE 1B Additional GW1843 Liposomal Formulations GW1843 concentration Median Molar mg/ml Dia-Preparation Ratio of in final meter I.D. Lipids lipids product nm pH AL1230-058 HSPC: Cholesterol 4:1 2.7 29 6.5 AL1230-052 DOPC: Cholesterol 2:1 1.4 30 6.3 AL1230-048 DEPC: Cholesterol 2:1 1.9 26 6.9 AL1230-055 Soy-PC: Cholesterol 2:1 1.5 43 6.6 AL1230-041 HSPC: Cholesterol: 2:1:0.1 3.6 43 6.3 DSPG

Previous Doc Next Doc Go to Doc#

## **Refine Search**

### Search Results -

Terms	Documents
L1 and phosphatidylcholine	3

Database:


US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database **EPO Abstracts Database** JPO Abstracts Database Derwent World Patents Index

**IBM Technical Disclosure Bulletins** 

Search:

2	
	oxdot









## **Search History**

DATE: Thursday, March 08, 2007

**Purge Queries** 

Printable Copy

Create Case

Set Name Query

side by side

**Hit Count Set Name** 

result set DB=PGPB, USPT, USOC, EPAB, JPAB, DWPI, TDBD; PLUR=YES; OP=OR

<u>L2</u> L1 and phosphatidylcholine <u>L2</u>

L1 liposome same cisplatin same phosphatidylglycerol 3 L1

**END OF SEARCH HISTORY** 

## First Hit Fwd Refs

Previous Doc Next Doc Go to Doc#

**End of Result Set** 

Generate Collection Print

L2: Entry 3 of 3

File: USPT

Aug 31, 1999

DOCUMENT-IDENTIFIER: US 5945122 A

TITLE: Liposomes containing a cisplatin compound

#### Brief Summary Text (27):

In a preferred embodiment, the vesicle forming lipid is hydrogenated soy phosphatidylcholine and the derivatized vesicle forming lipid is distearyl phosphatidylethanolamine derivatized with polyethylene glycol.

#### Detailed Description Text (9):

The vesicle-forming lipids of this type are preferably ones having two hydrocarbon chains, typically acyl chains, and a polar head group. There are a variety of synthetic vesicle-forming lipids and naturally-occurring vesicle-forming lipids, including the phospholipids, such as <a href="https://phosphatidyleholine">phosphatidyleholine</a> (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA), phosphatidylinositol (PI), and sphingomyelin (SM), where the two hydrocarbon chains are typically between about 14-22 carbon atoms in length, and have varying degrees of unsaturation. A preferred lipid for use in the present invention is hydrogenated soy phosphatidylcholine (HSPC).

## Detailed Description Text (56):

In the present invention, the liposome composition is typically prepared with between about 25-80 mole percent vesicle-forming lipids, 10-40 mole percent cholesterol, and 1-20 mole percent polymer-derivatized lipid. One exemplary liposome formulation includes hydrogenated soy <a href="https://phosphatidylcholine">phosphatidylcholine</a> (HSPC) and cholesterol (Chol), in about a 1:1 molar ratio, and between about 1-5 mole % of DSPE-PEG, added to form liposomes with an inner and outer bilayer surface coating of PEG.

#### Detailed Description Text (141):

<u>Cisplatin</u>-containing <u>liposomes</u> were prepared with no inner and outer surface coating of hydrophilic polymer chains for comparison to the <u>liposomes</u> of the present invention. Comparative <u>liposomes</u> were prepared as described in Example 3, except distearyl <u>phosphatidylglycerol</u> (DSPG) was substituted for the PEG-DSPE derivative, e.g., the <u>liposome</u> composition consisted of HSPC/Chol/DSPG in a molar ratio of 50.6/44.3/5.1.

### CLAIMS:

5. The composition of claim 1, wherein said vesicle forming lipid is hydrogenated soy <u>phosphatidylcholine</u> and said derivatized vesicle forming lipid is distearyl phosphatidylethanolamine derivatized with polyethylene glycol.

Previous Doc Next Doc Go to Doc#

# **Refine Search**

## Search Results -

Terms	Documents	
depc same dspg	5	

US Patents Full-Text Database
US OCR Full-Text Database
EBO Abstracts Database

US Pre-Grant Publication Full-Text Database


Database:

EPO Abstracts Database
JPO Abstracts Database


Derwent World Patents Index IBM Technical Disclosure Bulletins

Search:

L6 Refine Sea
1 ************************************







## Search History

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGI	PB, USPT, USOC, EPAB, JPAB, DWPI, TDBD; PLUR = Y.	ES; $OP = OR$	·
<u>L6</u>	depc same dspg	5	<u>L6</u>
<u>L5</u>	L4 and depc	1	<u>L5</u>
<u>L4</u>	liposome same cholesterol same dspg	123	<u>L4</u>
<u>L3</u>	liposome same depc same cholesterol same dspg	1	<u>L3</u>
<u>L2</u>	liposome same hspc same cholesterol same dspg	5	<u>L2</u>
<u>L1</u>	liposome same depc same cholesterol	4	L1

**END OF SEARCH HISTORY** 

First Hit Fwd Refs

Previous Doc Next Doc Go to Doc#

Cenerate Collection Print

L1: Entry 2 of 4

File: USPT

Jul 16, 1991

DOCUMENT-IDENTIFIER: US 5032404 A

\*\* See image for <u>Certificate of Correction</u> \*\*
TITLE: Lipsome-incorporation of polyenes

#### Detailed Description Text (72):

The respective MTD's (mg/kg) obtained for the various liposomal-mepartricin indicate the inclusion of <a href="mailto:cholesterol">cholesterol</a> precludes an immediate toxicity, with the exception of the <a href="mailto:DEPC">DEPC</a>:chol (9:1) mepartricin <a href="mailto:liposome">liposome</a>. Of these, particular lipid compositions were found to buffer the toxicity significantly. These were PC:chol (9:1), DOPC:PE:chol (7:3:1) and <a href="mailto:DEPC">DEPC</a>:PE:chol (7:3:1). FIGS. 9 and 10 show the survival rate and in vitro toxicity of free versus <a href="mailto:liposome">liposome</a>-encapsulated large polyenes, including mepartricin.

Previous Doc

Next Doc

Go to Doc#

First Hit Fwd Refs Previous Doc Next Doc

Generate Collection Print

L1: Entry 3 of 4

File: USPT

Go to Doc#

Mar 12, 1991

DOCUMENT-IDENTIFIER: US 4999199 A

\*\* See image for Certificate of Correction \*\*

TITLE: Pharmaceutical formulations: liposomes incorporating aromatic polyene

antibiotics

#### Detailed Description Text (10):

Candicidin was obtained from Dumex Co. (Copenhagen, Denmark) and was encapsulated in <a href="liposomes">liposomes</a> as follows: The lipids Egg phosphatidylcholine (EggPC), dimyristoyl phosphatidylcholine (DMPC), dimyristoyl phosphatidylglycerol (DMPG) dielaidoylphosphatidylcholine (DEPC) phosphatidylthanolamine (PE), dioleolylphosphatidylcholine (DOPC), distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylcholine (DPPC) and <a href="cholesterol">cholesterol</a>, were obtained from Avanti Polar lipids (Birmingham, Ala).

### Detailed Description Text (11):

Candicidin was dissolved in methanol at a concentration of 30 mg/ml, and the candicidin solution was added to the DMPC/cholesterol, the latter two lipids being mixed in a ratio of 9:1. The mixture was placed in a rotary evaporator, until the organic solvents were completely removed. Sterile normal saline was then added and <a href="https://lipide.com

Previous Doc Next Doc Go to Doc#

First Hit Fwd Refs

<u>Previous Doc</u> <u>Next Doc</u> <u>Go to Doc#</u>

Generate Collection Print

L2: Entry 4 of 5

File: USPT

Jun 2, 1998

DOCUMENT-IDENTIFIER: US 5759571 A

TITLE: Antibiotic formulation and use for drug resistant infections

#### CLAIMS:

11. A composition for treating a bacterial infection in a patient consisting essentially of amikacin encapsulated in <a href="liposomes">liposomes</a>, wherein the liposomes are comprised of <a href="cholesterol">cholesterol</a>, <a href="https://HSPC">HSPC</a>, and <a href="https://DSPG">DSPG</a> wherein <a href="https://HSPC:cholesterol:DSPG">HSPC:cholesterol:DSPG</a> are in a molar ratio of about 2:1:0.1 wherein the amikacin to total lipid molar ratio is from 1:9 to 1:3 and wherein said <a href="liposomes">liposomes</a> consist of unilamellar vesicles having an average size of less than 100 nm.

Previous Doc Next

Next Doc

Go to Doc#

First Hit

**Previous Doc** 

Next Doc

Go to Doc#

Generate Collection Print

L6: Entry 3 of 5

File: PGPB

Mar 25, 2004

DOCUMENT-IDENTIFIER: US 20040057990 A1

TITLE: Liposomal benzoquinazoline thymidylate synthase inhibitor formulations

## Detail Description Table CWU:

3TABLE 1B Additional GW1843 Liposomal Formulations GW1843 Molar concentration Median Ratio of mg/ml in final Diameter Preparation I.D. Lipids lipids product nm pH AL1230-058 HSPC:Cholesterol 4:1 2.7 29 6.5 AL1230-052 DOPC:Cholesterol 2:1 1.4 30 6.3 AL1230-048 DEPC:Cholesterol 2:1 1.9 26 6.9 AL1230-055 Soy-PC:Cholesterol 2:1 1.5 43 6.6 AL1230-041 HSPC:Cholesterol:DSPG 2:1:0.1 3.6 43 6.3

Previous Doc

Next Doc

Go to Doc#

First Hit Previous Doc Next Doc

> Generate Collection Print

L6: Entry 4 of 5

File: PGPB

Go to Doc#

Mar 21, 2002

DOCUMENT-IDENTIFIER: US 20020034538 A1

TITLE: Liposomal benzoquinazolne thymidylate synthase inhibitor formulations

#### Detail Description Table CWU:

3TABLE 1B Additional GW1843 Liposomal Formulations GW1843 concen- tration Median Molar mg/ml Dia- Preparation Ratio of in final meter I.D. Lipids lipids product nm pH AL1230-058 HSPC: Cholesterol 4:1 2.7 29 6.5 AL1230-052 DOPC: Cholesterol 2:1 1.4 30 6.3 AL1230-048 DEPC: Cholesterol 2:1 1.9 26 6.9 AL1230-055 Soy-PC: Cholesterol 2:1 1.5 43 6.6 AL1230-041 HSPC: Cholesterol: 2:1:0.1 3.6 43 6.3 DSPG

> Previous Doc Next Doc Go to Doc#